In parallel, within the JAK2 MV study, the presence of JAK2 p.V617F in patients was not associated with hepatomegaly, splenomegaly, or blood count abnormalities (clinical or laboratory signs of MPN). Here, JAK2 is linked to myeloproliferative disorder.